SEARCH

SEARCH BY CITATION

References

  • 1
    Hunt RH, Bazzoli F. Review article: should NSAID/low-dose aspirin takers be tested routinely for H. pylori infection and treated if positive? Implications for primary risk of ulcer and ulcer relapse after initial healing. Aliment Pharmacol Ther 2004; 19: 916.
  • 2
    Hoshino T, Tsutsumi S, Tomisato W, Hwang HJ, Tsuchiya T, Mizushima T. Prostaglandin E2 protects gastric mucosal cells from apoptosis via EP2 and EP4 receptor activation. J Biol Chem 2003; 278: 127528.
  • 3
    Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004; 18: 790804.
  • 4
    Halter F, Tarnawski AS, Schmassmann A, Peskar BM. Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut 2001; 49: 44353.
  • 5
    Weissmann G. Aspirin. Sci Am 1991; 264: 8490.
  • 6
    Smith WL, Dewitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000; 69: 14582.
  • 7
    Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. Br Med J 1995; 310: 82730.
  • 8
    Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 2325.
  • 9
    Stange EF, Preclik G, Gerber K, et al. Prostaglandin synthesis in stomach and duodenal mucosa of the human: effect of aspirin with and without antacid. Z Gastroenterol 1987; 25: 1625.
  • 10
    Lee M, Cryer B, Feldman M. Dose effects of aspirin on gastric prostaglandins and stomach mucosal injury. Ann Intern Med 1994; 120: 1849.
  • 11
    Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347: 117586.
  • 12
    Romano M, Ricci V, Memoli A, et al. Helicobacter pylori up-regulates cyclooxygenase-2 mRNA expression and prostaglandin E2 synthesis in MKN 28 gastric mucosal cells in vitro. J Biol Chem 1998; 273: 285603.
  • 13
    Konturek JW, Dembinski A, Konturek SJ, Stachura J, Domschke W. Infection of Helicobacter pylori in gastric adaptation to continued administration of aspirin in humans. Gastroenterology 1998; 114: 24555.
  • 14
    McCarthy CJ, Crofford LJ, Greenson J, Scheiman JM. Cyclooxygenase-2 expression in gastric antral mucosa before and after eradication of Helicobacter pylori infection. Am J Gastroenterol 1999; 94: 121823.
    Direct Link:
  • 15
    Kim JS, Kim JM, Jung HC, Song IS. Expression of cyclooxygenase-2 in human neutrophils activated by Helicobacter pylori water-soluble proteins: possible involvement of NF-kappaB and MAP kinase signaling pathway. Dig Dis Sci 2001; 46: 227784.
  • 16
    Meyer F, Ramanujam KS, Gobert AP, James SP, Wilson KT. Cutting edge: cyclooxygenase-2 activation suppresses Th1 polarization in response to Helicobacter pylori. J Immunol 2003; 171: 39137.
  • 17
    Futagami S, Hiratsuka T, Tatsuguchi A, et al. Monocyte chemoattractant protein 1 (MCP-1) released from Helicobacter pylori stimulated gastric epithelial cells induces cyclooxygenase 2 expression and activation in T cells. Gut 2003; 52: 125764.
  • 18
    Jackson LM, Wu KC, Mahida YR, Jenkins D, Hawkey CJ. Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa. Gut 2000; 47: 76270.
  • 19
    Tatsuguchi A, Sakamoto C, Wada K, et al. Localisation of cyclooxygenase 1 and cyclooxygenase 2 in Helicobacter pylori related gastritis and gastric ulcer tissues in humans. Gut 2000; 46: 7829.
  • 20
    Nardone G, Rocco A, Vaira D, et al. Expression of COX-2, mPGE-synthase1, MDR-1 (P-gp), and Bcl-xL: a molecular pathway of H. pylori-related gastric carcinogenesis. J Pathol 2004; 202: 30512.
  • 21
    Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 116181.
  • 22
    Malfertheiner P, Enrique D, Heckenmuller H, Neubrand M, Fischer HP, Sauerbruch T. Modified rapid urease test for detection of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1996; 8: 536.
  • 23
    Leodolter A, Dominguez-Munoz JE, von Arnim U, Kahl S, Peitz U, Malfertheiner P. Validity of a modified 13C-urea breath test for pre- and posttreatment diagnosis of Helicobacter pylori infection in the routine clinical setting. Am J Gastroenterol 1999; 94: 21004.
    Direct Link:
  • 24
    Wex T, Treiber G, Lendeckel U, Malfertheiner P. A two-step method for the extraction of high-quality RNA from endoscopic biopsies. Clin Chem Lab Med 2003; 41: 10337.
  • 25
    Feldman M, Shewmake K, Cryer B. Time course inhibition of gastric and platelet COX activity by acetylsalicylic acid in humans. Am J Physiol Gastrointest Liver Physiol 2000; 279: G111320.
  • 26
    Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999; 117: 1725.
  • 27
    Wallace JL, Zamuner SR, McKnight W, et al. Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation. Am J Physiol Gastrointest Liver Physiol 2004; 286: G7681.
  • 28
    Fiorucci S, Santucci L, Wallace JL, et al. Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proc Natl Acad Sci USA 2003; 100: 1093741.
  • 29
    Cryer B, Lee E, Feldman M. Factors influencing gastroduodenal mucosal prostaglandin concentrations: roles of smoking and aging. Ann Intern Med 1992; 116: 63640.
  • 30
    Hudson N, Balsitis M, Filipowicz F, Hawkey CJ. Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993; 34: 74851.
  • 31
    Mertz-Nielsen A, Hillingso J, Frokiaer H, Bukhave K, Rask-Madsen J. Gastric bicarbonate secretion and release of prostaglandin E2 are increased in duodenal ulcer patients but not in Helicobacter pylori-positive healthy subjects. Scand J Gastroenterol 1996; 31: 3843.
  • 32
    Cryer B, Faust TW, Goldschmiedt M, Redfern JS, Lee E, Feldman M. Gastric and duodenal mucosal prostaglandin concentrations in gastric or duodenal ulcer disease: relationships with demographics, environmental, and histological factors, including Helicobacter pylori. Am J Gastroenterol 1992; 87: 174754.
  • 33
    Preclik G, Abedin G, Stange EF, Baczako K, Ditschuneit H. Endogenous prostaglandin synthesis and gastritis: lack of correlation with endoscopic findings, Helicobacter colonization and leukocytic infiltration of the mucosa. Z Gastroenterol 1992; 30: 1303.
  • 34
    Fu S, Ramanujam KS, Wong A, et al. Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. Gastroenterology 1999; 116: 131929.
  • 35
    Wu CY, Wu MS, Chen CJ, Li MC, Lin JT, Chen GH. The interaction of H. pylori infection and NSAIDs in cyclooxygenase-2 mRNA expression in gastric antral, corpus mucosa, and gastric ulcer. J Clin Gastroenterol 2005; 39: 505.